Vaccinating Immunocompromised Patients: How Can Rates Rise?
The arrival of flu and COVID season once again brings to attention the fact that people with autoimmune and immune-mediated inflammatory diseases continue to be vaccinated at suboptimal rates despite their elevated risk for infection and poorer outcomes. In recent years, however, programs in rheumatology clinics have provided examples of successful approaches to address this problem against the headwinds of vaccine hesitancy and real-world challenges in implementing vaccination recommendations. And a national-level initiative is working to bring more evidence to the table to both prevent and treat infections in immunocompromised people. Maria Danila, MD “The vaccination coverage in rheumatic diseases continues to remain relatively low [compared to the general population] despite the higher infection risk in patients with autoimmune and rheumatic diseases,” Maria Danila, MD, UAB Endowed Professor in Musculoskeletal Outcomes Research and director of patient-oriented research at the University of Alabama at Birmingham, told Medscape Medical News . Patients with rheumatic diseases have as much as a 100% greater risk for hospitalization and mortality from seasonal influenza than the general population, according to a July 2026 network meta-analysis of 51 studies. While US government targets put the flu vaccine coverage rate at 70%, the pooled influenza vaccination rates in the meta-analysis for patients with rheumatoid arthritis , systemic lupus erythematosus , spondyloarthritis, and psoriatic arthritis were 50%, 42%, 43%, and 53%, respectively. Corresponding rates of pneumococcal vaccination in patients were 37%, 30%, 39%, and 41%. Low vaccination rates are not limited to people with autoimmune conditions. A January analysis from the CDC showed that flu vaccination coverage was 50.2% among children aged 6 months through 17 years in 2024-2025, a decline of 5.3 percentage points from the 2023-2024 flu season and 13.5 percentage points lower than the 2019-2020 pre-pandemic season. Coverage among adults aged 18 years or older was 41.9% for the same 2024-2025 flu season, a decrease of 3.0 percentage points from the previous season. In both cases, there may be an intuitive explanation for at least part of the cause of the decline in coverage. Vaccine Fatigue and Hesitancy “It could be vaccine fatigue from the pandemic,” Kevin Winthrop, MD, MPH, professor of medicine with the Division of Infectious Diseases at Oregon Health & Science University School of Medicine in Portland, told Medscape Medical News . “Everyone got vaccinated a lot, particularly people at high risk for severe outcomes. So there were a lot of vaccinations given and people got tired. So I think vaccine fatigue is a real phenomenon, and it’s kind of played out since the pandemic.” Kevin Winthrop, MD, MPH Hesitancy is another familiar and widespread factor that persists despite public education efforts and exists across large cross-sections of the patient population, including in people with rheumatic diseases. “I think we’re seeing vaccine hesitancy for sure,” Vidya Sivaraman, MD, associate professor of clinical pediatrics at The Ohio State University and a pediatric rheumatologist with Nationwide Children’s Hospital in Columbus, Ohio, told Medscape Medical News . “The communication challenges continue.... When you start broadening out to the community, you see they’re getting their information from a variety of different sources. I’ve had patients come to appointments with various printouts or links to videos [and they say] ‘Hey, this is what this says.’ And that’s not actually what is going on. These are real and serious issues.” Vidya Sivaraman, MD A variety of studies have indicated that some popular disease-modifying antirheumatic drugs (DMARDs) appear safe to use during vaccination. Recently, results from a large clinical trial published in October in JAMA Internal Medicine found that pausing biologic or targeted synthetic DMARDs following a COVID booster vaccine did not enhance immunogenicity in people with autoimmune diseases. In fact, patients who paused their treatment experienced more disease flares than those who didn’t. The decision to pause a given therapy, of course, rests largely on which agents are involved. For examples, it is typically recommended to hold methotrexate because it can attenuate a vaccine response. Guidelines from the American College of Rheumatology (ACR) and other organizations are essential documents that provide recommendations on a range of vaccination topics. However, these recommendations are not always easy to implement, particularly for rank-and-file rheumatology clinics. “I think there’s a lot of recommendations made that don’t necessarily get put into practice because they’re difficult to do,” said Winthrop, who was involved in creating the ACR vaccination guidelines. “Maybe, for example, you want to vaccinate your patient, but you can’t actually do it because they have to get that particular one at the pharmacy. It’s only rolled out through pharmacies. So, flu vaccine, you probably have in your clinic. You can probably do that yourself.” Meanwhile, as biologic drugs’ effects on immune cell kinetics shape the treatment of rheumatologic diseases, day-to-day issues such as vaccination may be inadvertently de-prioritized, experts said. Joshua A. Hill, MD “The immunocompromised patient population is really a rapidly growing population within the US and worldwide as we have developed more drugs to treat autoimmune conditions,” Joshua A. Hill, MD, associate professor of the infectious disease sciences program in the Vaccine and Infectious Disease Division of Fred Hutch Cancer Center in Seattle, told Medscape Medical News . As patients live longer lives with immune-compromising conditions, Hill said, “we’ve seen less investment in the supportive care aspects of taking care of those patients. And a big part of that is preventing and treating infectious diseases.” However, researchers continue to conduct studies to determine when or whether to pause certain agents during the vaccination period and what vaccines are safe. According to Winthrop, more understanding of this question could increase patient confidence. “The other thing that’s really complicated around these people we’re talking about, and maybe it is a gray area between the guidelines and daily practices, but what do you do with their DMARDs?” he said. “Do you stop them temporarily? Do you keep them going? I mean, a lot of the studies I’ve been interested in and doing and pursuing with colleagues is...to figure out this issue. If you’re on drug X, do you need to hold it while I give you the vaccine, and does it benefit you to do that? So really, the one drug that’s very clear to hold is methotrexate, and that’s been figured out over the last 5 or 6 years.” Approaches to Improve Vaccination Rates Many vaccine-optimization efforts involve two key tentpoles: better communication among all parties and engaging other health professionals and clinical staff besides just the physician. Even as questions about the pharmacokinetic effects of treatments on aspects such as B-cell depletion and repopulation persist, there are process improvements that can reap benefits in the clinic. “Every year, we kind of target different things that we’d like to improve,” explained Sivaraman, who serves as director of quality improvement at Nationwide Children’s Hospital. “This year, we’ve targeted the pneumococcal vaccine — a new vaccine that came out a few years ago. Our patients need just one extra dose of that vaccine, and so we’re just improving our messaging with patients. It can take a lot of time. But we finally just this past month made a real leap, and it was because our nurses started helping us too, reminding us [about vaccinations] because we’re doing so many things in our patient visits that it’s really hard to cover everything.” In one study , presented at the at ACR 2025 Annual Meeting, patients received a questionnaire at each visit to assess vaccine status and interest. At the same time, providers and clinic staff received training on the importance of vaccinating immunosuppressed patients and identifying eligible patients using the questionnaire and electronic medical record (EMR) care gap alerts. Following the intervention, the clinic saw a marked rise in vaccination rates, with 144 influenza vaccines administered — a 108.9% increase — and 170 pneumococcal 20-valent conjugate vaccines administered, reflecting an 8400% increase. In another program , researchers relied heavily on the EMR to increase vaccination rates, creating a best practice alert (BPA) in the EMR system that alerts providers when a patient is due for either a pneumococcal 13-valent conjugate vaccine (PCV-13) or 23-valent pneumococcal polysaccharide vaccine (PPSV-23). The BPA then opened an order set, with the provider signing the vaccine order and a nurse administering the vaccine as part of the checkout process. Of 50 patient charts reviewed preintervention from January 2019, 31% were up to date on PCV-13 and 49% were up to date on the PPSV-23. In January 2020, post-intervention, 60% were up to date on PCV-13 and 78% were up to date on PPSV-23. One of the most comprehensive initiatives on vaccination among immunocompromised patients took place in 2020 at a large US Department of Veterans Affairs rheumatology clinic in the Midwest. The program’s staying power over time has been a hallmark of its success. The initial results, which were published in The Journal for Healthcare Quality , showed a 20-percentage-point rise in vaccination rates after clinical staff learned Lean Six Sigma, a process improvement methodology with steps to better define, measure, analyze, and control a given system or practice. Melissa Swee, MD “We used the framework with an interprofessional team, and the clinic nurse manager was the process owner,” study co-author Melissa Swee, MD, a clinical assistant professor of internal medicine in the Division of Nephrology at University of Iowa Carver College of Medicine in Iowa City, told Medscape Medical News . “Mapping the process showed that one vaccine took about 15 minutes of nursing time, most of it spent on a clerk deciding whether the nurse was free, re-rooming the patient, and walking 30 feet to a supply room. We ran three Plan-Do-Study-Act cycles. The first was clinician education, the second posted simplified guidelines at the point of care, and the third changed the workflow so that clinicians messaged the nurse directly, patients stayed in their room, and supplies were consolidated into a kit by the exam rooms. The vaccination rate rose from 3% to 23%, and administration time fell from 15 minutes to 7 minutes.” Those improvements have been sustained over time, with vaccination rates at the clinic currently approaching 75%. Swee credited newer conjugate vaccines that provide more coverage in a single dose but added that Lean Six Sigma, and the teamwork it helps to foster, remains valuable for improving vaccination rates. “Measure first because most clinics overestimate their rate,” Swee advised. “Build the team around the people who touch the vaccine, the nurse who gives it, and the front desk staff who move patients, not just the physicians. Education is necessary but will not hold on its own, so pair it with a process change. Nurse-driven standing orders, [BPA s] in the EMR, and previsit planning have all worked in other rheumatology clinics, and the common thread is that the physician is not the only person who can start the process.” ImmunOptimize Network Aims to Generate More Evidence Changes are underway at the research level that could ultimately bring new knowledge or treatments to these vulnerable populations. At Fred Hutch, Hill helped develop the ImmunOptimize Network , a national clinical trials infrastructure that launched in 2024 and is designed to educate patients and the public, accelerate clinical studies of strategies aimed at preventing and treating infections in immunocompromised patients, and ultimately develop clinical trials to evaluate novel and existing therapeutics for infectious diseases in these populations. “What we’ve heard from industry is that it’s challenging to do studies in patients with autoimmune disease or with cancer because at any given place, these patients, there’s not as many of them and it’s harder to recruit and enroll,” Hill said. “They’ve got more adverse events and complexity. So companies are a little bit resistant to get into this space. But we’ve been working toward setting up the infrastructure to be able to bring those patient populations and expertise to the table in a kind of network across major centers in the US and North America to be able to do these sorts of studies and to be able to partner with industry to say, ‘Hey, we can help you with this. We’ve got this established infrastructure. This lowers the barrier to you. It kind of de-risks you investing in this space so that we can do these studies.’” Danila has received research funding and payments for consulting services from Amgen and payments for development of educational materials from Medscape. Winthrop reported receiving consulting fees from AbbVie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, GSK, Moderna, Novartis, Oruka, Ouros, Otsuka, Roche, Sanofi, Takeda, UCB, and Zura Bio. Hill reported consulting for Sanofi, Merck, Takeda, GSK, CSL Behring, GeoVax, and Moderna and receiving research grants from Sanofi, Takeda, CSL Behring, GeoVax, and Gilead. Swee and Sivaraman reported no relevant disclosures. Scott Harris has been covering rheumatology for more than a decade. He lives near Washington, DC.